Background. Hypertension and atrial fibrillation are a fairly common combination of heart pathology that occurs in the daily practice of a cardiologist. Associations of clinical laboratory and instrumental indicators with the levels of various biomarkers, in particular serum N-terminal fragment of brain natriuretic propeptide (NT-proBNP), are interesting and promising for scientific research and practical application.
The aim of the study was to simulate the clinical profiles of patients with hypertension and atrial fibrillation depending on the serum levels of NTpro-BNP.
Materials & Methods. 89 patients with stage II hypertension and various clinical forms of atrial fibrillation were included in the study. All patients underwent a general clinical examination, additional determination of NT-proBNP serum levels, and assessment of quality of life according to the Minnesota Living with Heart Failure Questionnaire (MLHFQ) for 2–3 days of hospital stay at against the background of selection of optimal therapy. Sequential statistical processing of the obtained data using Spearman’s rank correlation analysis and multiple linear regression made it possible to create two clinical profiles of patients.
Results & conclusions. Thus, with a relatively high serum level of NTpro-BNP (≥810 ng/l), the following will be characteristic: hypertensive history >12 years; the presence of signs of left ventricular hypertrophy on the ECG according to the Sokolov-Lyon criteria; increase in the right atrium >36 mm and systolic pressure in the pulmonary artery >38 mm Hg according to Echocardiography; an increase in the average daily heart rate >110 per 1 min with Holter ECG monitoring; a decrease in the glomerular filtration rate <56 ml/min/1.73m2 and an increase in the total MLHFQ score >27. The dominant markers of a relatively high level of NTpro-BNP were a decrease in quality of life, instrumental signs of hemodynamic overload of the right heart and clinically significant cardiorenal disorders. With a relatively low serum level of NTpro-BNP (≤220 ng/l), the following will be characteristic: hypertensive history anamnesis <8 years; lack of signs of the left ventricle hypertrophy on the ECG according to the Sokolov-Lyon criteria; the size of the right atrium <34 mm and/or the value of systolic pressure in the pulmonary artery <33 mm Hg according to Echocardiography; average daily heart rate with Holter ECG monitoring <92 per 1 minute; glomerular filtration rate >68 ml/min/1.73m2 and the total MLHFQ score <21. The dominant markers of a relatively low level of NTpro-BNP were the absence of signs of left ventricular hypertrophy on the ECG and a balanced state of sympatho-adrenal activity by the nature of circadian regulation of heart rate.
Keywords: atrial fibrillation; N-terminal fragment of brain natriuretic propeptide; clinical profile of patients.
Su L, Sun L, Xu L. Review on the prevalence, risk factors and disease Management of Hypertension among floating population in China during 1990–2016. Glob Health Res Policy. 2018;3:24. DOI: 10.1186/s41256-018-0076-9. PMID: 30123839.
Perry M, Kemmis BS, Downes N, Andrews N, Mackenzie S; Guideline Committee. Atrial fibrillation: diagnosis and management-summary of NICE guidance. BMJ. 2021;373:n1150. DOI: 10.1136/bmj.n1150. PMID: 34020968.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hy-pertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. PMID: 32370572. DOI: 10.1161/HYPERTENSIONAHA.120.15026.
Xu L, Chen Y, Ji Y, Yang S. Influencing factors of NT-proBNP level inheart failure patients with different car-diacfunctions and correlation with prognosis. Exp Ther Med. 2018;15(6):5275-80. DOI: 10.3892/etm.2018.6114. PMID: 29904410.
Yoo J, Grewal P, Hotelling J, Papamanoli A, Cao K, Dhaliwal S, et al. Admission NT-proBNP and outcomes in patients without history of heart failure hospitalized with COVID-19. ESC Heart Fail. 2021;8(5):4278-87. DOI: 10.1002/ehf2.13548. PMID: 34346182.
McCormack T, Boffa RJ, Jones NR, Carville S, McManus RJ. The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ. Eur Heart J. 2019;40(42):3456-8. DOI: 10.1093/eurheartj/ehz681. PMID: 31589745.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the Eu-ropean Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021;42(5):507. Erratum in: Eur Heart J. 2021;42(5):546-7. Erra-tum in: Eur Heart J. 2021;42(40):4194. PMID: 32860505.
Bilbao A, Escobar A, Garcia-Perez L, Navarro G, Quiros R. The Minnesota living with heart failure question-naire: comparison of different factor structures. Health Qual Life Outcomes. 2016;14:23. DOI: 10.1186/s12955-016-0425-7. PMID: 26887590.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.